{"classes":[{"categories":[{"measurements":[{"comment":"6 of 6 patients enrolled on Dose Level 1 and 5 of 10 patients at dose level 2 were DLT-evaluable. Therefore, the primary outcome of determining the safety and tolerability beyond dose level one was not possible, and the MTD and recommended phase 2 dose could not be evaluated prior to study closure.","groupId":"OG000","value":"NA"},{"comment":"6 of 6 patients enrolled on Dose Level 1 and 5 of 10 patients at dose level 2 were DLT-evaluable. Therefore, the primary outcome of determining the safety and tolerability beyond dose level one was not possible, and the MTD and recommended phase 2 dose could not be evaluated prior to study closure.","groupId":"OG001","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"groups":[{"description":"KRT-232 60 mg + KRd","id":"OG000","title":"Part A: Dose Level 1"},{"description":"KRT-232 90 mg + KRd","id":"OG001","title":"Part A: Dose Level 2"}],"paramType":"NUMBER","populationDescription":"Only included DLT-evaluable patients. 6 of 6 patients enrolled on Dose Level 1 and 5 of 10 patients at dose level 2 were DLT-evaluable. Therefore, the primary outcome of determining the safety and tolerability beyond dose level one was not possible, and the MTD and recommended phase 2 dose could not be evaluated prior to study closure.","reportingStatus":"POSTED","timeFrame":"at least 6 months of treatment, an average of 1 year","title":"Determine Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of KRT-232 (AMG 232) in Combination With Carfilzomib, Lenalidomdie, and Dexamethasone (KRd)","type":"PRIMARY","unitOfMeasure":"mg"}